Document:

Document

Exhibit 10.1

                    
						
	Hideki Garren
[Address Redacted]
	REVISED – March 18, 2021

Dear Hideki:

I am pleased to confirm this offer for you to join Prothena Biosciences Inc (“Prothena” or the “Company”).  We are confident in your knowledge, expertise and judgment, and believe your performance will meet our team’s high-quality objectives and standards.

Your start date will be April 5, 2021, and the Prothena Corporation plc Board of Directors will appoint you as Chief Medical Officer effective April 5, 2021, subject to your commencement of employment with the Company that day.  In this position, you will report to Gene Kinney (President and CEO), although your duties, title and reporting relationship may change, based on the Company’s needs and priorities.  This is a full-time, exempt position – which means that you are not eligible for overtime pay under state and federal laws. 

Your starting annualized salary will be $490,000.00 (gross), paid twice per month.  Your pay is subject to applicable taxes and withholdings.

We agree to pay you a Retention Bonus of $50,000.00 (gross) which will be fully earned in the event that you remain employed with Prothena for one year.  The entire Retention Bonus will be paid to you with your first paycheck, less applicable taxes and withholdings.  This Retention Bonus will be earned on a pro-rata basis for each week worked during your initial one-year period of your employment at Prothena.  The unearned portion of this Retention Bonus will be repayable by you to Prothena on a pro-rata basis if you cease employment at Prothena prior to the one-year anniversary of your employment start date, unless your employment ends for a reason that would make you eligible for severance benefits in accordance with the Prothena Biosciences Inc Amended and Restated Severance Plan.  The forgoing will be set forth in a Retention Bonus Repayment Agreement, a form of which is attached (Exhibit 1), that we will need you to sign on your start date in order to receive the Retention Bonus.

Prothena embraces a pay-for-performance philosophy.  All employees are currently eligible for an annual cash bonus under the terms of the Company's cash incentive plan (the Prothena Corporation plc Amended and Restated Incentive Compensation Plan).  The amount of these annual cash bonuses is determined by the Company on the basis of a number of factors, including industry competitiveness, Prothena’s business strategy, and the degree to which Company, function and/or individual goals are met.  Your targeted cash bonus for our 2021 performance year will be 50% of your actual salaried earnings during that year.1  A condition of earning any cash incentive award is that you remain employed through the pay date of an otherwise earned award, which will be paid no later than March 15, 2022.  The cash bonus plan is operated at the sole discretion of Prothena, is subject to review on a regular basis and may change from time to time.

1 For the 2021 performance year, rather than using your actual salary earned, your annualized base salary of $490,000.00 will be used as your salaried earnings

                                                                                           

In connection with your start date and appointment as CMO, you will also be eligible to receive an option to acquire 250,000 shares of Prothena Corporation plc. This stock option award is at the discretion of the Compensation Committee of the Board of Directors of Prothena Corporation plc (the “Committee”) and is subject to the approval, and terms and conditions of the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (as amended) and the terms and conditions of the award agreement for such a stock option. The grant date of this stock option will be April 5, 2021, the date you start with Prothena and are appointed CMO, or on such other date as determined by the Committee in its sole discretion. The option exercise price will be equal to the closing price of Prothena Corporation plc’s ordinary shares on the NASDAQ Global Select Market on that date. Subject to your continued employment, the stock option will vest 25% on the first anniversary of the grant date, and monthly at a rate of 1/48th of the award thereafter, such that the option will fully vest after a four-year period following the grant date.

On the first day of the month following your employment start date, you will be eligible to participate in Prothena’s comprehensive health and welfare benefits program.  On your start date, you will also be eligible to participate in our retirement benefits plan, as well as the Prothena Biosciences Inc Amended and Restated Severance Plan (Tier I).  Details about these and other applicable plans will be provided separately.

The Company provides paid vacation time to full-time employees in accordance with the Company’s vacation policy in its Employee Handbook, which will be provided to you upon commencement of your employment.  You will also be eligible for paid sick time as required by state law.  Additional information about paid sick time is contained in the Company’s Employee Handbook.  

Further information regarding onboarding requirements and/or documents needed on your employment start date (e.g., Employee Proprietary Information and Invention Assignment Agreement, Code of Conduct, Form I-9 completion process, direct deposit information, Form W-4 allowance elections) will be provided separately.

This offer is contingent upon your successful completion of a background check and a pre-employment drug test.  More information regarding this process will be provided by Human Resources.

Additionally, your acceptance of this offer of employment and commencement of that employment means that you understand and agree that your employment relationship with the Company is at-will, for no specific period, and neither this letter nor any other oral or written representations may be considered a contract of employment for any specific period of time.  As a result, you are free to resign your employment with Prothena at any time, for any reason or no reason.  Similarly, Prothena is also free to end your employment at any time, with or without cause or advance notice.  At-will employment also means that the Company may make decisions regarding other terms of your employment at any time with or without advance notice or cause, including but not limited to demotion, promotion, transfer, discipline, compensation and duties.  Further, all benefits and compensation provided by the Company are contingent upon your continued employment.

                                                                                           

To accept our offer, please sign this letter and return it to Kevin Hickey (VP, Human Resources) by Monday, March 22, 2021.  This offer is valid until then, after which time we will not be able to accommodate an acceptance of this offer.  Accordingly, please sign and return this letter before the above-stated expiration date.  If you do not intend to accept this offer, we would like to be notified as soon as possible. 

This letter, along with the Company’s policies and procedures, sets forth the terms of your employment with the Company if you accept this offer and commence that employment, and supersedes any prior representations or agreements, whether written or oral.  This letter may be modified only by a written agreement signed by you and an authorized officer of the Company.

We look forward to having you join Prothena as a full-time employee.  If you have any questions, or if you would like additional information to help you reach a decision, please feel free to contact Kevin at (650) 278-1762.  Please be sure to bring with you on you first day of employment documentation that proves your eligibility to work in the U.S., your bank details and emergency contact information.

Sincerely,

/s/ Gene G. Kinney
Gene Kinney
President and CEO
Prothena Biosciences Inc

ACCEPTANCE:

/s/ Hideki Garren                            March 19, 2021
Hideki Garren                            Date

                                                                                           

Exhibit 1 – RETENTION BONUS REPAYMENT AGREEMENT

I, Hideki Garren, will receive $50,000.00 (gross) as a Retention Bonus with my first paycheck, less applicable withholdings and deductions, from Prothena Biosciences Inc (“Prothena” or the “Company”), which will not be fully earned until I have provided 12 months of Active Service as described below.

I understand and agree that a key purpose of the Retention Bonus is my retention as an employee, that the Retention Bonus is being paid to me before it is earned, and that I have not earned the Retention Bonus until I complete 12 months of continuous Active Service.  For purposes of this Retention Bonus, “Active Service” includes periods from my employment start date that I am continuously employed by the Company or its affiliates, including time off for approved vacation, holidays, personal time, family & medical leave, and military leave, but not other leaves of absence unless otherwise required by applicable law.

I understand and agree that if I complete 12 months of Active Service from my employment start date, then I have earned this Retention Bonus and have no obligation to repay any portion of it upon termination of my employment.

I further understand and agree that if my employment terminates for any reason (other than if my employment ends for a reason that would make me eligible for severance benefits in accordance with the Prothena Biosciences Inc Amended and Restated Severance Plan) prior to my completion of 12 months of Active Service from my start date, then I must repay a pro-rata amount of the Retention Bonus in one lump sum within 30 days of my termination date.  Within 5 days of my employment end date, the Company will notify me in writing of the amount to be repaid.

If I fail to repay the amount due under this Retention Bonus Repayment Agreement (this “Agreement”) within 30 days of the termination of my employment, then the Company may bring legal proceedings against me for collection.  I further agree that for any claims brought by the Company to enforce the terms of this Agreement, the prevailing party will be entitled to costs and reasonable attorneys’ fees.

I agree and understand that nothing in this Agreement alters the at-will nature of my employment with Prothena, meaning that my employment is for no definite period and may be terminated either by me or the Company at any time, with or without cause or advance notice.

I acknowledge that I understand the terms of this Agreement, that I have had an opportunity to consult with counsel or another advisor prior to signing it, and that I agree to abide by its terms.  I am voluntarily signing this Agreement.

ACCEPTANCE:

[TO BE SIGNED AND DATED ON DAY 1 OF EMPLOYMENT]

___________________________________        ____________________
Hideki Garren                        DateDocument

Exhibit 10.2

SEVENTH AMENDMENT TO THE
PROTHENA CORPORATION PLC
2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN

This Seventh Amendment (this “Seventh Amendment”) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (“2020 EIIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the “Company”), on February 1, 2021 (the “Amendment Date”).

RECITALS

WHEREAS, the Company maintains the 2020 EIIP; and

WHEREAS, the Board believes it is in the best interests of the Company and its shareholders to amend the 2020 EIIP to increase the number of ordinary shares authorized for issuance under the 2020 EIIP.

NOW, THEREFORE, BE IT RESOLVED, that the 2020 EIIP is hereby amended as follows, effective as of the Amendment Date:

AMENDMENT

1.Section 2.28 of the 2020 EIIP is hereby amended and restated in its entirety as follows:

“2.28 “Overall Share Limit” means 785,000 Shares.”

2.This Seventh Amendment shall be and hereby is incorporated into and forms a part of the 2020 EIIP, and except as expressly provided herein, all terms and conditions of the 2020 EIIP shall remain in full force and effect.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]